Chronic Obstructive Pulmonary Disease — A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
Citation(s)
A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease